An implantable device comprising a coating, the coating comprising: a reservoir layer comprising a biodegradable semi-crystalline polymer, and a primer comprising a biodegradable amorphous polymer, wherein the amorphous polymer has a miscibility of at least 5% in the semi-crystalline polymer, wherein the coating has a degradation or absorption rate that within a period of 6 months after deployment of the implantable device, the coating has a mass loss of 80% or more, wherein the semi-crystalline polymer is selected from the group consisting of semi-crystalline poly(L-lactide-co-glycolide) (PLLGA) with content of L-lactide ranging from 65 molar% to 100 molar%, semi-crystalline poly(L-lactic acid-co-glycolide-co-caprolactone) (PLLA-GA-CL) terpolymer with content of L-lactide ranging from 65 molar% or higher, semi-crystalline poly(L-lactic acid-co-caprolactone) (PLLA-CL) (L-lactide/CL = 75/25 or 70/30 by molar), and combinations thereof, and wherein the amorphous polymer is selected from the group consisting of amorphous poly(D,L-lactide) (PDLA), amorphous poly(L-lactide-co-D,L-lactide) (PLLLA) with D,L-lactide content of 30 molar % or above, amorphous poly(D,L-lactide-co-glycolide) (PDLGA) with glycolide content of 10 to 50 molar%, amorphous poly(L-lactide-co-glycolide) (PLLGA) with L-lactide content of 75 molar% or below, amorphous poly(glycolide-co-caprolactone) (PGACL) with glycolide content of 70 molar% or below, amorphous poly(D,L-lactide-co-caprolactone) (PDLACL) with caprolactone content of 70 molar% or below, amorphous poly(L-lactide-co-caprolactone) (PLLACL) with L-lactide content of below 70 molar% but above 30 molar%, amorphous copolymers of trimethylene carbonate with glycolide, D,L-lactide, and/or L-lactide, amorphous poly(D,L-lactide-co-glycolide-co-caprolactone) (PDLGA-CL) and PLLA-GA-CL terpolymers with content of L-lactide of 65 molar% or below, and combinations thereof. a reservoir layer comprising a biodegradable semi-crystalline polymer, and a primer comprising a biodegradable amorphous polymer, wherein the amorphous polymer has a miscibility of at least 5% in the semi-crystalline polymer, wherein the coating has a degradation or absorption rate that within a period of 6 months after deployment of the implantable device, the coating has a mass loss of 80% or more, wherein the semi-crystalline polymer is selected from the group consisting of semi-crystalline poly(L-lactide-co-glycolide) (PLLGA) with content of L-lactide ranging from 65 molar% to 100 molar%, semi-crystalline poly(L-lactic acid-co-glycolide-co-caprolactone) (PLLA-GA-CL) terpolymer with content of L-lactide ranging from 65 molar% or higher, semi-crystalline poly(L-lactic acid-co-caprolactone) (PLLA-CL) (L-lactide/CL = 75/25 or 70/30 by molar), and combinations thereof, and wherein the amorphous polymer is selected from the group consisting of amorphous poly(D,L-lactide) (PDLA), amorphous poly(L-lactide-co-D,L-lactide) (PLLLA) with D,L-lactide content of 30 molar % or above, amorphous poly(D,L-lactide-co-glycolide) (PDLGA) with glycolide content of 10 to 50 molar%, amorphous poly(L-lactide-co-glycolide) (PLLGA) with L-lactide content of 75 molar% or below, amorphous poly(glycolide-co-caprolactone) (PGACL) with glycolide content of 70 molar% or below, amorphous poly(D,L-lactide-co-caprolactone) (PDLACL) with caprolactone content of 70 molar% or below, amorphous poly(L-lactide-co-caprolactone) (PLLACL) with L-lactide content of below 70 molar% but above 30 molar%, amorphous copolymers of trimethylene carbonate with glycolide, D,L-lactide, and/or L-lactide, amorphous poly(D,L-lactide-co-glycolide-co-caprolactone) (PDLGA-CL) and PLLA-GA-CL terpolymers with content of L-lactide of 65 molar% or below, and combinations thereof.